GNRH1 and prostate carcinoma: In prostate cancer, where the goal is to attain and maintain profound castrate levels of testosterone, the challenge is to deliver sufficiently high initial amounts of peptide into the circulation to compete against endogenous GnRH and occupy pituitary GnRH receptors 100%.